Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
With few pipeline catalysts this year the pressure is growing on Lundbeck's new chief executive, Deborah Dunsire, to deliver a deal. But the company only has $5bn to…
Takeda's appetite for risk in early stage neuroscience could make it one to watch.